Old Web
English
Sign In
Acemap
>
authorDetail
>
Mary-Anne B. MacKay
Mary-Anne B. MacKay
University of Alberta
Psychology
Psychiatry
Biomarker (medicine)
Schizophrenia
Antidepressant
4
Papers
94
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (4)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Ketamine as an antidepressant: overview of its mechanisms of action and potential predictive biomarkers.
2020
Therapeutic Advances in Psychopharmacology
Dmitriy Matveychuk
Rejish K Thomas
Jennifer Swainson
Atul Khullar
Mary-Anne B. MacKay
Glen B. Baker
Serdar M. Dursun
Show All
Source
Cite
Save
Citations (17)
Esketamine for treatment resistant depression
2019
Expert Review of Neurotherapeutics
Jennifer Swainson
Rejish K Thomas
Shaina Archer
Carson Chrenek
Mary-Anne B. MacKay
Glen B. Baker
Serdar M. Dursun
Larry J. Klassen
Pratap Chokka
Michael L Demas
Show All
Source
Cite
Save
Citations (26)
D-Serine: Potential Therapeutic Agent and/or Biomarker in Schizophrenia and Depression?
2019
Frontiers in Psychiatry
Mary-Anne B. MacKay
Maryana Kravtsenyuk
Rejish K Thomas
Nicholas Mitchell
Serdar M. Dursun
Glen B. Baker
Show All
Source
Cite
Save
Citations (44)
Multidimensional Connectomics and Treatment-Resistant Schizophrenia: Linking Phenotypic Circuits to Targeted Therapeutics
2018
Frontiers in Psychiatry
Mary-Anne B. MacKay
John W. Paylor
James T.F. Wong
Ian R. Winship
Glen B. Baker
Serdar M. Dursun
Show All
Source
Cite
Save
Citations (7)
1